JERUSALEM, August 30, 2022 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced the Company will participate in person at three upcoming investor conferences in September 2022.
Citi's 17th Annual BioPharma Conference
Wednesday, September 7,2022
Cantor Oncology, Hematology & HemeOnc Conference
Wednesday, September 28th, 2022
New York, NY
Group Panel and 1:1 Meetings
Ladenburg Thalmann Annual Healthcare Conference
Thursday, September 29th, 2022
New York, NY
Company Presentation and 1:1 Meetings
Additional information can be found on the Events and Presentations section of Alpha Tau’s investor
website, www.alphatau.com/events. If you would like to schedule a 1:1 meeting, please contact the appropriate institutional representative.
About Alpha DaRT™
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli medical device company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
Investor Relations Contact